1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Zhejiang Zhenyuan Share Co., Ltd.

Zhejiang Zhenyuan Share Co., Ltd.

000705.SZ
Zhejiang Zhenyuan Share Co., Ltd.CN flagShenzhen Stock Exchange
6.14
CNY
-0.17
- -
2.05BMarket Cap
Zhejiang Zhenyuan Share Co., Ltd.
000705.SZ
(Shenzhen Stock Exchange)

Recent

price

6.14

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
6.06
6.82
6.84
5.95
6.39
6.46
7.54
7.6
8.47
9.66
10.39
10.75
12.24
12.07
10.77
7.02
9.17
Revenue per Share
0.08
0.12
0.18
0.19
0.12
0.1
0.14
0.18
0.21
0.63
0.27
0.23
0.23
0.24
0.1
0.07
0.14
Basic EPS, GAAP
0.09
-0.18
0.28
-0.39
-0.08
-0.43
0.23
0.04
-0.07
0.09
0.34
0.01
-0.37
-0.3
-0.74
-0.45
-0.85
Free Cash Flow per Basic Share
0.06
0.03
0.04
0.03
0.01
- -
0.04
0.02
- -
0.03
0.06
0.07
0.06
0.06
0.07
0.08
0.08
Dividend per Share
0.93
1.03
1.31
1.18
1.86
1.9
2.07
2.12
2.33
2.94
3.18
3.27
3.41
3.74
3.68
3.94
3.93
Book Value per Share
2.05
2.02
4.05
3.36
3.64
3.72
3.91
3.86
4.19
4.93
5.16
5.41
5.41
5.54
5.33
5.79
5.72
Tangible Book Value per Share
248
252
265
339
326
335
323
339
338
336
331
336
339
340
347
324
334
Basic Weighted Avg Shares
1,503
1,719
1,812
2,018
2,081
2,165
2,440
2,578
2,858
3,243
3,440
3,612
4,145
4,106
3,741
2,276
3,065
Sales/Revenue/Turnover
2.25
2.8
3.67
3.79
2.34
1.55
2.16
2.37
2.84
2.62
2.47
2.33
2.68
2.36
1.36
0.63
1.3
Operating Margin (%)
31
32
33
26
29
42
47
54
57
54
54
89
92
101
98
103
- -
Depreciation Expense
21
32
48
64
39
34
45
61
71
212
89
77
78
82
35
23
47
Net Income, GAAP
15.2
18.55
20.31
16.05
15.46
14.99
20.04
18.7
15.75
16.73
18.93
21.64
20.06
22.9
32.41
37.34
18.12
Effective Tax Rate (%)
1.4
1.83
2.63
3.19
1.88
1.55
1.86
2.37
2.48
6.52
2.6
2.14
1.88
1.99
0.93
1
1.55
Profit Margin (%)
173
163
699
627
594
475
420
498
567
906
890
1,005
1,015
1,092
955
641
817
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
76
48
53
55
165
164
209
LT Debt
548
548
1,110
1,178
1,223
1,283
1,314
1,390
1,498
1,712
1,762
1,872
1,947
1,999
1,962
1,975
2,012
Total Equity
4.7
5.91
5.85
5.65
3.48
2.35
3.25
3.64
4.75
4.4
3.75
3.34
4.45
3.67
1.53
0.38
1.46
Return on Invested Capital (%)
6.69
8.87
13.62
16.25
7.48
5.35
6.6
7.97
8.86
22.68
7.77
6.4
6.27
6.12
2.39
1.55
3.33
Return on Capital (%)
9.41
12.88
15.69
17.22
7.77
5.4
6.94
8.8
9.41
23.85
8.77
7.19
6.91
6.73
2.73
1.78
3.64
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
316
66
95
LT Borrowings
129
167
169
LT Finance Leases
36
39
41
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
334
334
334
Market Capitalization
2,643
2,646
2,823

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
2,150
1,467
1,450
Cash, Cash Equivalents & STI
549
503
513
Accounts Receivable, Net
693
363
328
Inventories
717
506
524
Total Current Liabilities
1,194
571
633
Payables & Accruals
- -
- -
- -
ST Debt
316
66
95
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.5%
2.35%
0.68%
Free Cash Flow
-369.94%
-647.27%
-42.97%
Net Income, GAAP
12.66%
-20.01%
-34.66%
Sales/Revenue/Turnover
1.95%
-5.85%
-39.17%
Total Cash Common Dividend
489%
5.61%
13.22%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,045
914
893
889
3,741
2025
752
532
496
- -
2,276
2026
441
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
- -
- -
- -
0.1
2025
0.11
- -
- -
- -
0.07
2026
-0.07
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.07
2025
0.01
- -
- -
- -
0.08
2026
- -
- -
- -
- -
- -
Similar Companies
Roche Holding AG (ROG.SW)
Scilex Holding Company (SCLX)
Luye Pharma Group Ltd. (2186.HK)
Impact Therap-b (7630.HK)
Kyowa Kirin Co., Ltd. (KYKOF)
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ)
Business
Zhejiang Zhenyuan Share Co., Ltd. (000705.SZ) manufactures, wholesales and distributes pharmaceuticals primarily in China with some international operations. The company offers Chinese herbal medicines, herbal medicine slices, patent medicines; pharmaceutical raw materials, chemical preparations, antibiotics, biochemical drugs, biological products, medical devices, chemical reagents and glass instruments; pharmaceutical logistics and health services; as well as medicines, pre-packaged foods and dairy products including infant formula milk powder. It operates through pharmaceutical wholesale, manufacturing, distribution and health services segments targeting hospitals, pharmacies and consumers. Founded in 1993 and headquartered in Shaoxing, Zhejiang Province, China, the company traces its heritage to Zhenyuantang established in 1752 and listed on the Shenzhen Stock Exchange in 1997 as the first company recommended by the State Administration of Traditional Chinese Medicine. Recent developments include plans announced in September 2024 to publicly list its wholly-owned subsidiary Shaoxing Zhenyuan Pharmaceuticals Co., Ltd. via equity trading to optimize asset allocation and boost profitability in pharmaceutical wholesale; termination of a planned share issuance to specific investors; a change in controlling shareholder equity structure in early 2025 with Shaoxing State-owned Capital Operation Co., Ltd. acquiring stakes in Shaoxing Zhenyuan Health Industry Group under local state-owned enterprise reform; and an agreement in February 2025 to acquire an 11.26% stake in Zhejiang Zhenyuan Pharmaceutical Chain Co., Ltd. for CNY 37 million alongside a prior 10.89% minority interest purchase in July 2024 to consolidate its retail pharmacy operations.